RESUMO
The synthetic peptide CIGB-210 is a promising anti-HIV drug candidate shown to inhibit HIV replication in MT4 cells at the nanomolar range by triggering the rearrangement of vimentin intermediate filaments. Sensitive and specific analytical methods are required for pharmacological studies of CIBG-210 in animals. In this study, we describe the development of a competitive ELISA for the quantitative determination of CIGB-210 using an anti-CIGB-210 hyperimmune serum. After optimization of all the steps, the assay exhibited a dynamic range from 11.87 to 0.0095 µg/mL. The intra-assay coefficient of variation (CV) was lower than or close to 5% for all the six concentrations of the calibrator, and the inter-assay CV was below 10% in five out of the six concentrations tested. No interference of either murine or human plasma was observed. The analyte was stable in plasma after five freeze-thaw cycles, while the hyperimmune serum maintained its binding capacity after 10 freeze-thaw cycles. Furthermore, the ELISA was able to detect the two main metabolites of CIGB-210, although with a tenfold decrease in sensitivity. Our results demonstrate the utility and feasibility of this analytical method for pharmacological experiments in animals as humans.
Assuntos
Fármacos Anti-HIV/análise , Fármacos Anti-HIV/sangue , Líquidos Corporais/química , Ensaio de Imunoadsorção Enzimática , Animais , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/química , Humanos , Camundongos , Peptídeos/análise , Peptídeos/sangue , Peptídeos/síntese química , Peptídeos/químicaRESUMO
Analiza los factores asociados a la comunidad de Rota, Malpaisillo de mayo a junio del 2003. El objetivo general es identificar los factores asociados a la transmisión de la Leishmaniasis Cutánea atípica, describir la ecología dle vector, así como el abordaje terapéutico de dichos pacientes y las posibles infecciones de Leishmaniasis Cutánea Atípica.